OBJECTIVE: The early course of illness in psychotic disorders is highly variable, and predictive biomarkers of treatment response have been lacking. Trial and error remains the basis for care in early psychosis, and poor outcomes are common. Early prediction of nonimprovement in response to treatment could help identify those who would benefit from alternative and/or supplemental interventions. The goal of this study was to evaluate the ability of functional MRI (fMRI) measures of cognitive control-related brain circuitry collected at baseline to predict symptomatic response in patients after 1 year. METHODS: Patients with recent-onset (<2 years) psychotic disorders (N=82) in early psychosis specialty care were classified as improvers (>20% improvement in total score on the Brief Psychiatric Rating Scale [BPRS] at 1-year follow-up compared with baseline) or as nonimprovers. Behavioral (d' context) and fMRI (proactive control-associated activation in a priori frontoparietal regions of interest) measures of cognitive control were then evaluated on their ability to predict BPRS improvement using linear and logistic regression. RESULTS: Cognitive control-associated measures significantly predicted BPRS improvement and improver status, with 70% positive predictive value, 60% negative predictive value, and 66% accuracy. Only the fMRI-based measure (and not the behavioral measure) significantly predicted status. CONCLUSIONS: These results suggest that frontoparietal activation during cognitive control performance at baseline significantly predicts subsequent symptomatic improvement during early psychosis specialty care. Potential implications for fMRI-based personalized patient treatment are discussed.
OBJECTIVE: The early course of illness in psychotic disorders is highly variable, and predictive biomarkers of treatment response have been lacking. Trial and error remains the basis for care in early psychosis, and poor outcomes are common. Early prediction of nonimprovement in response to treatment could help identify those who would benefit from alternative and/or supplemental interventions. The goal of this study was to evaluate the ability of functional MRI (fMRI) measures of cognitive control-related brain circuitry collected at baseline to predict symptomatic response in patients after 1 year. METHODS:Patients with recent-onset (<2 years) psychotic disorders (N=82) in early psychosis specialty care were classified as improvers (>20% improvement in total score on the Brief Psychiatric Rating Scale [BPRS] at 1-year follow-up compared with baseline) or as nonimprovers. Behavioral (d' context) and fMRI (proactive control-associated activation in a priori frontoparietal regions of interest) measures of cognitive control were then evaluated on their ability to predict BPRS improvement using linear and logistic regression. RESULTS: Cognitive control-associated measures significantly predicted BPRS improvement and improver status, with 70% positive predictive value, 60% negative predictive value, and 66% accuracy. Only the fMRI-based measure (and not the behavioral measure) significantly predicted status. CONCLUSIONS: These results suggest that frontoparietal activation during cognitive control performance at baseline significantly predicts subsequent symptomatic improvement during early psychosis specialty care. Potential implications for fMRI-based personalized patient treatment are discussed.
Authors: Tristram A Lett; Aristotle N Voineskos; James L Kennedy; Brian Levine; Zafiris J Daskalakis Journal: Biol Psychiatry Date: 2013-09-05 Impact factor: 13.382
Authors: Bo Cao; Raymond Y Cho; Dachun Chen; Meihong Xiu; Li Wang; Jair C Soares; Xiang Yang Zhang Journal: Mol Psychiatry Date: 2018-06-19 Impact factor: 15.992
Authors: Dori Henderson; Andrew B Poppe; Deanna M Barch; Cameron S Carter; James M Gold; John D Ragland; Steven M Silverstein; Milton E Strauss; Angus W MacDonald Journal: Schizophr Bull Date: 2012-01 Impact factor: 9.306
Authors: Jong H Yoon; Michael J Minzenberg; Stefan Ursu; B S Ryan Walter; Ryan Walters; Carter Wendelken; J Daniel Ragland; Cameron S Carter Journal: Am J Psychiatry Date: 2008-06-02 Impact factor: 18.112
Authors: Tyler A Lesh; Andrew J Westphal; Tara A Niendam; Jong H Yoon; Michael J Minzenberg; J Daniel Ragland; Marjorie Solomon; Cameron S Carter Journal: Neuroimage Clin Date: 2013-04-22 Impact factor: 4.881
Authors: Jason Smucny; Tyler A Lesh; Vanessa C Zarubin; Tara A Niendam; J Daniel Ragland; Laura M Tully; Cameron S Carter Journal: Schizophr Bull Date: 2020-01-05 Impact factor: 9.306
Authors: Jason Smucny; Laura M Tully; Amber M Howell; Tyler A Lesh; Sheri L Johnson; Randall C OʼReilly; Michael J Minzenberg; Stefan Ursu; Jong H Yoon; Tara A Niendam; J Daniel Ragland; Cameron S Carter Journal: Neuropsychopharmacology Date: 2021-01-15 Impact factor: 7.853
Authors: Przemysław Adamczyk; Martin Jáni; Tomasz S Ligeza; Olga Płonka; Piotr Błądziński; Miroslaw Wyczesany Journal: Brain Topogr Date: 2021-05-10 Impact factor: 3.020
Authors: Annie Blazer; K N Roy Chengappa; William Foran; Ashley C Parr; Charles E Kahn; Beatriz Luna; Deepak K Sarpal Journal: Psychopharmacology (Berl) Date: 2022-04-18 Impact factor: 4.415